ARAVIVE, INC (ARAV) vs Valion Bio, Inc. (VBIO)

ARAVIVE, INC and Valion Bio, Inc. are both Biotechnology companies. ARAVIVE, INC and Valion Bio, Inc. are of similar size ($3.0M and $3.0M). ARAVIVE, INC grew revenue faster over the last twelve months: −19.1% against −49.6%. Valion Bio, Inc. has the higher net margin (0.00% vs −569.7%) and the lower return on invested capital (−61.0% vs 0.00%). Across the 18 metrics below, ARAVIVE, INC leads on 10 and Valion Bio, Inc. on 8.

Valuation

Metric ARAV VBIO Biotechnology median
P/E n/m n/m 7.88
P/S 0.43 0.84 11.47
P/B 1.78 0.10 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA 0.05 n/m 0.74
EV/Sales (0.44) 11.80 10.73
Earnings yield (1,500.00%) (6,048.69%) (28.84%)
Free cash flow yield (2,072.58%) (3,751.73%) (23.03%)

Profitability

Metric ARAV VBIO Biotechnology median
Gross margin 100.00% (58.09%) 65.16%
Operating margin (847.42%) 0.00% 0.00%
Net margin (569.65%) 0.00% 0.00%
Free cash flow margin (849.92%) 0.00% 0.00%
Return on equity (475.98%) (489.30%) (57.72%)
Return on assets (144.19%) (104.96%) (49.22%)
Return on invested capital 0.00% (61.01%) 0.00%

Growth

Metric ARAV VBIO Biotechnology median
Revenue growth (TTM) (19.11%) (49.63%) 5.64%
EPS growth (last fiscal year) (7.69%) 60.16% —
Revenue growth, 5-year CAGR (25.57%) 13.18% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ARAV VBIO Biotechnology median
Debt to equity 0.18 0.62 0.00
Current ratio 0.98 1.11 4.73
Net debt to EBITDA 0.74 0.79 0.96

Dividend

Metric ARAV VBIO Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ARAV VBIO Biotechnology median
Market cap 2.95m 2.97m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack